The anti-tumour effect of low-dose continuous chemotherapy may partly be mediated by thrombospondin

Impaired recruitment of bone-marrow–derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth

David Lyden, Koichi Hattori, Sérgio Dias et al. · Nature Medicine · 2001 · 1.9K citations

Angiogenesis, Medicine, Stem Cell Mobilization +11

Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer.

Timothy M. Browder, Catherine Butterfield, Birgit M. Kräling et al. · PubMed · 2000 · 1.6K citations

Tumor Biology, Chemoprevention Strategy, Medicine +14

Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies.

A. Eberhard, Sebastian Kahlert, Valentin Goede et al. · PubMed · 2000 · 755 citations

Endothelial Cells, Vascular Malformation, Pathology +18

A Multitargeted, Metronomic, and Maximum-Tolerated Dose “Chemo-Switch” Regimen is Antiangiogenic, Producing Objective Responses and Survival Benefit in a Mouse Model of Cancer

Kristian Pietras, Douglas Hanahan · Journal of Clinical Oncology · 2004 · 476 citations · Full text

Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy

Guido Bocci, Giulio Francia, Shan Man et al. · Proceedings of the National Academy of Sciences · 2003 · 415 citations · Full text

Antiangiogenic Effects, Endothelial Cells, Activated Endothelial Cells +23